SIGA - SIGA Technologies EV/EBITDA Multiple

Attracting virologists through government social benefit packages provides SIGA Technologies, Inc. (SIGA) with resilience against macro cycles. The EV/EBITDA ratio, accounting for operating profit and amortization, confirms this trend, where the value of 0.00 expresses the metric level. Regular procurement of the TPOXX drug by various national ministries of health to ensure global biological security completes the financial stability.

SIGA TPOXX: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/14/2026

Analytical breakdowns for SIGA Technologies, Inc.

- stock price and consensus target price:

Stock Quotes SIGA Corp|SIGA - Price Target Chart

- market capitalization statistics:

Market Capitalization TPOXX|SIGA - Company Buyout Price

- issuer book value statistics:

Net Assets per Single Share SIGA Technologies|SIGA - Accounting Value of Company|Market Cap to Net Assets Ratio siga.com|SIGA - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

SIGA - Net Profit|Future Profit SIGA Technologies, Inc.|SIGA - Company Value to Net Income|Projected Price to Earnings SIGA Technologies, Inc.|SIGA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple TPOXX|SIGA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) SIGA Technologies|SIGA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth siga.com|SIGA - Earnings per share increase in current year|Net earnings per share growth forecast for next year SIGA Technologies, Inc.

- company sales and revenue statistics:

SIGA - Company Sales Volume|Company Projected Revenue SIGA Corp|SIGA - Price to Sales|Price-to-Projected Revenue Ratio TPOXX

Comprehensive company analysis:SIGA Corp SIGA

EV/EBITDA determines the value of a company relative to its operating profit before interest and taxes, allowing for an assessment of the real value of assets without the influence of debt load. By analyzing the EV/EBITDA multiple history of the business, an investor can see the efficiency of capital management, which is critical for SIGA Technologies, Inc. (SIGA) given the high costs associated with establishing government stockpiles and specialized drug logistics.

Analysis of competing companies

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio EBS|EV/EBITDA Multiple Atea Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Invivyd, Inc. (IVVD)|Total Company Value to Operating Income Before Depreciation Ratio enanta.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inovio INO|Total Company Value to Operating Income Before Depreciation Ratio HilleVax Inc (HLVX)|Kalaris Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dyadic International DYAI|NNVC: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple talphera.com TLPH|COCP (Cocrystal Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Traws Therapeutics|Enterprise Value to EBITDA Ratio DWTX (Dogwood Therapeutics, Inc.)|QLGN (Qualigen Corp) - Business Value to Operating Income Before Depreciation|AlloVir - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio VBIV (VBI Vaccines, Inc.)|Virios - EV/EBITDA Multiple|Company Value to EBITDA Vaxart, Inc.